Lecture 2 Paper 2

🧬 Big Picture: Why Site-Selective Protein Modification Matters

Nature constantly modifies proteins after translation using post-translational modifications (PTMs) such as phosphorylation, glycosylation, acetylation, methylation, and ubiquitination. These small chemical changes can:

• Switch enzymes on or off
• Alter protein–protein interactions
• Change solubility, stability, and localization
• Introduce new chemical functions not present in the 20 standard amino acids

💡 Core idea of the paper: Chemists aim to mimic nature by developing chemical reactions that modify proteins at one specific, pre-defined site, rather than randomly. This enables precision biology, imaging, and drug development.

❌ The Problem with Early Protein Modification Chemistry

Early methods (e.g. NHS esters) react with many lysines at once, producing:

• Heterogeneous mixtures
• Poor reproducibility
• Difficult structure–function analysis
• Reduced or lost biological activity

🚨 This is unacceptable for:

• Mechanistic biology
• Imaging probes
• Therapeutic proteins

➡️ Solution: Site-selective protein-modification chemistry.

🎯 What Is Site-Selective Protein Modification?

Definition: A reaction that forms a covalent bond between a protein and a synthetic molecule at one specific residue.

Key requirements:

• Chemoselective (one residue only)
• Compatible with water, neutral pH, 20–37 °C
• Does not disrupt protein folding
• Stable linkage (especially in vivo)

🧪 Two Major Strategies

1️⃣ Natural amino acids (mostly Cys and N-terminus)

• Works mainly in vitro
• Requires purified proteins
• Limited selectivity in complex mixtures

2️⃣ Non-canonical (unnatural) amino acids

• Introduced via genetic code expansion
• Carry unique handles (azide, alkyne, ketone, alkene, tetrazine)
• Enable bioorthogonal chemistry
• Work in cells and living organisms

🧠 Bioorthogonal Chemistry (Core Concept)

Bioorthogonal reactions:

• Do not react with native cellular chemistry
• Are fast, selective, and non-toxic
• Allow protein-specific labeling inside cells or animals

Typical handles:

• Azide ↔ alkyne (CuAAC)
• Tetrazine ↔ strained alkene (IEDDA)
• Ketone ↔ hydroxylamine (oxime ligation)

🧬 Studying Post-Translational Modifications (PTMs)

Why PTMs are hard to study:

• Natural PTMs are often rare
• Isolation of single modified isoforms is difficult
• Enzymatic systems can be complex and context-dependent

🧩 Total and Semi-Synthesis Approaches

Native Chemical Ligation (NCL)

• Joins peptide fragments via N-terminal Cys
• Allows exact PTM placement
• Excellent precision, poor scalability

Expressed Protein Ligation (EPL)

• Combines synthetic peptides + recombinant proteins
• Ideal when PTMs are near protein termini

📌 Classic example:

• Histone H3 Arg42 dimethylation
• Showed direct transcriptional activation

🧪 Chemical Installation of PTM Mimics on Folded Proteins

Instead of native PTMs, chemists install PTM mimics:

🔁 Cys → Dehydroalanine (Dha)

• Cys chemically converted to Dha
• Dha reacts with nucleophiles (Michael addition)

Examples:

• Phosphorylation mimics (phospho-Cys)
• Acetyl-Lys and methyl-Lys mimics
• Functional histone analogues

💡 Key insight: Many mimics are biologically indistinguishable from native PTMs.

🧷 Ubiquitination by Chemical Ligation

Ubiquitination is especially challenging because it forms isopeptide bonds.

Chemical solutions include:

• δ-thiol-Lys incorporation + NCL
• Protected Lys strategies
• Bioorthogonal polymerization of ubiquitin chains

🚀 Enables:

• Site-specific mono- and poly-ubiquitination
• Controlled studies of signaling pathways

🔬 Protein Modification for Imaging

Why site-selectivity matters:

• In vivo behavior depends on label position
• FRET requires precise dye placement
• Double labeling demands orthogonal chemistry

🧪 In Vitro Labeling

• Maleimides, haloacetamides, Michael acceptors
• Mostly single-site, purified proteins

🧫 In Vivo & Live-Cell Labeling

Using bioorthogonal chemistry:

• Proteins labeled inside living cells
• Minimal background
• High spatial and temporal precision

Examples:

• Norbornene–tetrazine labeling on cell surfaces
• “Turn-on” fluorophores (low background)
• Tracking toxin uptake and trafficking

🧠 Protein-Based Biosensors

By combining:

• Non-canonical amino acids
• Environment-sensitive dyes
• FRET pairs

Researchers created sensors for:

• pH
• Ca²⁺ concentration
• Protein conformational changes

📍 Example:

• Dual-labeled calmodulin reporting Ca²⁺ levels inside living cells

💊 Modifying Therapeutic Proteins

The problem:

• Rapid clearance
• Proteolysis
• Immunogenicity
• Loss of efficacy

🧴 PEGylation (and Its Limits)

PEGylation:

• Increases hydrodynamic radius
• Reduces kidney filtration
• Shields from immune system

🚨 Traditional PEGylation:

• Random
• Often reduces activity

✅ Site-Selective PEGylation Strategies

1. N-terminal oxidation → oxime ligation
2. Direct N-terminal aldehyde chemistry
3. Genetic encoding of ketone-bearing amino acids

📌 Clinical example:

• Site-selective PEGylated human growth hormone
• Improved pharmacokinetics
• Reduced injection frequency

🎯 Antibody–Drug Conjugates (ADCs)

Why site-selectivity is critical:

• Drug-to-antibody ratio (DAR) affects:
  • Stability
  • Toxicity
  • Clearance
• Attachment site influences:
  • Efficacy
  • Off-target effects

🧪 Cys-Based ADC Chemistry

• Engineered cysteines + maleimides
• Can achieve DAR ≈ 2
• But: maleimides can be unstable in plasma

🛠 Fixes:

• Ring-opened maleimides
• Neighboring amines
• Alternative thiol-reactive chemistries

🧬 Bioorthogonal ADCs (Next-Gen)

• Unnatural amino acids (e.g. p-acetyl-Phe)
• Stable linkages
• Homogeneous products
• Improved in vivo performance

📈 Result:

• Better tumor targeting
• Reduced toxicity
• Improved therapeutic index

🔓 In Situ Protein Activation (“Decaging”)

New frontier: activating proteins inside living cells

Strategies:

• Palladium-mediated deprotection
• Tetrazine-triggered Diels–Alder elimination
• Photocaged amino acids (light-activated)

🔥 Applications:

• Spatiotemporal control of protein function
• Targeted pro-drug release
• Precision therapeutics

🔮 Conclusions & Outlook

Two flavors of site-selective modification:

🚀 The future:

• Multi-site modifications
• Live-cell functional studies
• Safer, more effective protein drugs
• Precision imaging and therapy

🧠 Key message: As bioorthogonal chemistry becomes easier and more accessible, site-selective protein modification will transform biology, imaging, and medicine.